OrthoPediatrics Q1 Revenue Up 13% to $59.4M, Guidance Raised to $263–$267M
OrthoPediatrics posted Q1 revenue of $59.4M, up 13% year-over-year, with domestic sales up 11% and international up 22%, and achieved adjusted EBITDA of $2.2M versus a $0.4M loss last year. It cut free cash flow usage by 40% and raised full-year revenue guidance to $263M–$267M.
1. First Quarter Financial Results
OrthoPediatrics posted first quarter revenue of $59.4 million, a 13% increase from $52.4 million a year ago. Domestic sales rose 11% to $45.3 million while international revenue climbed 22% to $14.1 million, driven by strong organic growth in Trauma & Deformity and Scoliosis products, and adjusted EBITDA turned positive at $2.2 million versus a $0.4 million loss last year.
2. Cash Flow and Liquidity
Free cash flow usage improved by 40% to $5.0 million, reflecting lower set deployments and stronger working capital management. As of March 31, cash, cash equivalents, short-term investments and restricted cash totaled $50.9 million, down from $62.9 million at year-end 2025.
3. Full-Year Guidance Update
The company increased its 2026 revenue guidance to a range of $263.0 million to $267.0 million, representing 11% to 13% growth over 2025, raising the midpoint by $0.5 million from prior estimates. This adjustment reflects sustained momentum across both domestic and international markets.
4. Specialty Bracing Portfolio Expansion
OrthoPediatrics expanded its Specialty Bracing (“OPSB”) portfolio with the launch of the TRAXIO Halo Gravity Traction system. The mechanical, weight-based traction device is designed to support controlled spinal realignment in pediatric scoliosis patients within hospital environments, reinforcing the company’s comprehensive pediatric spine care offerings.